Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 24 entries
Sorted by: Best Match Show Resources per page
A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells.

Advances and applications in bioinformatics and chemistry : AABC

Ohyashiki JH, Hamamura R, Kobayashi C, Zhang Y, Ohyashiki K.
PMID: 21918608
Adv Appl Bioinform Chem. 2008;1:85-98. doi: 10.2147/aabc.s4133. Epub 2008 Oct 30.

There is a need to identify the regulatory gene interaction of anticancer drugs on target cancer cells. Whole genome expression profiling offers promise in this regard, but can be complicated by the challenge of identifying the genes affected by...

Cite
Ohyashiki JH, Hamamura R, Kobayashi C, et al. A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells. Adv Appl Bioinform Chem. 2008;1:85-98doi: 10.2147/aabc.s4133.
Ohyashiki, J. H., Hamamura, R., Kobayashi, C., Zhang, Y., & Ohyashiki, K. (2008). A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells. Advances and applications in bioinformatics and chemistry : AABC, 185-98. https://doi.org/10.2147/aabc.s4133
Ohyashiki, Junko H, et al. "A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells." Advances and applications in bioinformatics and chemistry : AABC vol. 1 (2008): 85-98. doi: https://doi.org/10.2147/aabc.s4133
Ohyashiki JH, Hamamura R, Kobayashi C, Zhang Y, Ohyashiki K. A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells. Adv Appl Bioinform Chem. 2008;1:85-98. doi: 10.2147/aabc.s4133. Epub 2008 Oct 30. PMID: 21918608; PMCID: PMC3169936.
Copy Download .nbib Format: NLM
Amyloid Angiopathy-related Severe Hemorrhage with Multiple Myeloma.

Internal medicine (Tokyo, Japan)

Katagiri S, Akahane D, Tanaka Y, Ohyashiki K.
PMID: 28943545
Intern Med. 2017 Nov 01;56(21):2957-2958. doi: 10.2169/internalmedicine.8609-16. Epub 2017 Sep 25.

No abstract available.

Cite
Katagiri S, Akahane D, Tanaka Y, et al. Amyloid Angiopathy-related Severe Hemorrhage with Multiple Myeloma. Intern Med. 2017;56(21):2957-2958doi: 10.2169/internalmedicine.8609-16.
Katagiri, S., Akahane, D., Tanaka, Y., & Ohyashiki, K. (2017). Amyloid Angiopathy-related Severe Hemorrhage with Multiple Myeloma. Internal medicine (Tokyo, Japan), 56(21), 2957-2958. https://doi.org/10.2169/internalmedicine.8609-16
Katagiri, Seiichiro, et al. "Amyloid Angiopathy-related Severe Hemorrhage with Multiple Myeloma." Internal medicine (Tokyo, Japan) vol. 56,21 (2017): 2957-2958. doi: https://doi.org/10.2169/internalmedicine.8609-16
Katagiri S, Akahane D, Tanaka Y, Ohyashiki K. Amyloid Angiopathy-related Severe Hemorrhage with Multiple Myeloma. Intern Med. 2017 Nov 01;56(21):2957-2958. doi: 10.2169/internalmedicine.8609-16. Epub 2017 Sep 25. PMID: 28943545; PMCID: PMC5709649.
Copy Download .nbib Format: NLM
Two Additional Acute Nonlymphocytic Leukemia Patients with a Sole Chromosome Abnormality of Trisomy 4.

Leukemia & lymphoma

Tauchi T, Ohyashiki K, Kodama A, Iwabuchi A, Ohyashiki JH, Toyama K.
PMID: 27456580
Leuk Lymphoma. 1990;2(1):131-5. doi: 10.3109/10428199009042523.

We report two cases of acute nonlymphocytic leukemia (ANLL) in which the circulating leukemic cells showed trisomy of chromosome 4 as the sole cytogenetic abnormality. Trisomy 4 is rarely found in hematopoietic neoplasia and until now the few reported...

Cite
Tauchi T, Ohyashiki K, Kodama A, et al. Two Additional Acute Nonlymphocytic Leukemia Patients with a Sole Chromosome Abnormality of Trisomy 4. Leuk Lymphoma. 1990;2(1):131-5doi: 10.3109/10428199009042523.
Tauchi, T., Ohyashiki, K., Kodama, A., Iwabuchi, A., Ohyashiki, J. H., & Toyama, K. (1990). Two Additional Acute Nonlymphocytic Leukemia Patients with a Sole Chromosome Abnormality of Trisomy 4. Leukemia & lymphoma, 2(1), 131-5. https://doi.org/10.3109/10428199009042523
Tauchi, T, et al. "Two Additional Acute Nonlymphocytic Leukemia Patients with a Sole Chromosome Abnormality of Trisomy 4." Leukemia & lymphoma vol. 2,1 (1990): 131-5. doi: https://doi.org/10.3109/10428199009042523
Tauchi T, Ohyashiki K, Kodama A, Iwabuchi A, Ohyashiki JH, Toyama K. Two Additional Acute Nonlymphocytic Leukemia Patients with a Sole Chromosome Abnormality of Trisomy 4. Leuk Lymphoma. 1990;2(1):131-5. doi: 10.3109/10428199009042523. PMID: 27456580.
Copy Download .nbib Format: NLM
Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.

Oncoimmunology

Yoshimoto T, Mizoguchi I, Katagiri S, Tauchi T, Furusawa JI, Chiba Y, Mizuguchi J, Ohyashiki JH, Ohyashiki K.
PMID: 25057448
Oncoimmunology. 2014 May 14;3:e28861. doi: 10.4161/onci.28861. eCollection 2014.

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive...

Cite
Yoshimoto T, Mizoguchi I, Katagiri S, et al. Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. Oncoimmunology. 2014;3:e28861doi: 10.4161/onci.28861.
Yoshimoto, T., Mizoguchi, I., Katagiri, S., Tauchi, T., Furusawa, J. I., Chiba, Y., Mizuguchi, J., Ohyashiki, J. H., & Ohyashiki, K. (2014). Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. Oncoimmunology, 3e28861. https://doi.org/10.4161/onci.28861
Yoshimoto, Takayuki, et al. "Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse." Oncoimmunology vol. 3 (2014): e28861. doi: https://doi.org/10.4161/onci.28861
Yoshimoto T, Mizoguchi I, Katagiri S, Tauchi T, Furusawa JI, Chiba Y, Mizuguchi J, Ohyashiki JH, Ohyashiki K. Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. Oncoimmunology. 2014 May 14;3:e28861. doi: 10.4161/onci.28861. eCollection 2014. PMID: 25057448; PMCID: PMC4091524.
Copy Download .nbib Format: NLM
Telomerase reactivation in leukemia cells.

International journal of oncology

Ohyashiki K, Ohyashiki J, Iwama H, Hayashi S, Shay J, Toyama K.
PMID: 21544377
Int J Oncol. 1996 Mar;8(3):417-21. doi: 10.3892/ijo.8.3.417.

We utilized fluorescent-labeled primers and modified the telomeric repeal amplification protocol (TRAP) to assess telomerase activity during the process of in vitro establishment in four different leukemia cell lines. We demonstrate that three of four leukemia cell lines had...

Cite
Ohyashiki K, Ohyashiki J, Iwama H, et al. Telomerase reactivation in leukemia cells. Int J Oncol. 1996;8(3):417-21doi: 10.3892/ijo.8.3.417.
Ohyashiki, K., Ohyashiki, J., Iwama, H., Hayashi, S., Shay, J., & Toyama, K. (1996). Telomerase reactivation in leukemia cells. International journal of oncology, 8(3), 417-21. https://doi.org/10.3892/ijo.8.3.417
Ohyashiki, K, et al. "Telomerase reactivation in leukemia cells." International journal of oncology vol. 8,3 (1996): 417-21. doi: https://doi.org/10.3892/ijo.8.3.417
Ohyashiki K, Ohyashiki J, Iwama H, Hayashi S, Shay J, Toyama K. Telomerase reactivation in leukemia cells. Int J Oncol. 1996 Mar;8(3):417-21. doi: 10.3892/ijo.8.3.417. PMID: 21544377.
Copy Download .nbib Format: NLM
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.

Cancer cell international

Okabe S, Tauchi T, Tanaka Y, Kimura S, Maekawa T, Ohyashiki K.
PMID: 23556431
Cancer Cell Int. 2013 Apr 04;13(1):32. doi: 10.1186/1475-2867-13-32.

BACKGROUND: The use of imatinib, an ABL tyrosine kinase inhibitor, has led to a dramatic change in the management of BCR-ABL-positive leukemia patients. However, resistance to imatinib mediated by mutations in the BCR-ABL domain has become a major problem...

Cite
Okabe S, Tauchi T, Tanaka Y, et al. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 2013;13(1):32doi: 10.1186/1475-2867-13-32.
Okabe, S., Tauchi, T., Tanaka, Y., Kimura, S., Maekawa, T., & Ohyashiki, K. (2013). Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer cell international, 13(1), 32. https://doi.org/10.1186/1475-2867-13-32
Okabe, Seiichi, et al. "Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells." Cancer cell international vol. 13,1 (2013): 32. doi: https://doi.org/10.1186/1475-2867-13-32
Okabe S, Tauchi T, Tanaka Y, Kimura S, Maekawa T, Ohyashiki K. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 2013 Apr 04;13(1):32. doi: 10.1186/1475-2867-13-32. PMID: 23556431; PMCID: PMC3635933.
Copy Download .nbib Format: NLM
Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells.

Frontiers in pharmacology

Imanishi S, Umezu T, Kobayashi C, Ohta T, Ohyashiki K, Ohyashiki JH.
PMID: 30386240
Front Pharmacol. 2018 Oct 16;9:1166. doi: 10.3389/fphar.2018.01166. eCollection 2018.

Recent investigations of the treatment for hematologic neoplasms have focused on targeting epigenetic regulators. The DNA methyltransferase inhibitor 5-azacytidine (AZA) has produced good results in the treatment of patients with myelodysplastic syndromes. The mechanism underlying its pharmacological activity involves...

Cite
Imanishi S, Umezu T, Kobayashi C, et al. Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells. Front Pharmacol. 2018;9:1166doi: 10.3389/fphar.2018.01166.
Imanishi, S., Umezu, T., Kobayashi, C., Ohta, T., Ohyashiki, K., & Ohyashiki, J. H. (2018). Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells. Frontiers in pharmacology, 91166. https://doi.org/10.3389/fphar.2018.01166
Imanishi, Satoshi, et al. "Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells." Frontiers in pharmacology vol. 9 (2018): 1166. doi: https://doi.org/10.3389/fphar.2018.01166
Imanishi S, Umezu T, Kobayashi C, Ohta T, Ohyashiki K, Ohyashiki JH. Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells. Front Pharmacol. 2018 Oct 16;9:1166. doi: 10.3389/fphar.2018.01166. eCollection 2018. PMID: 30386240; PMCID: PMC6198088.
Copy Download .nbib Format: NLM
HIV positivity may not have a negative impact on survival in Epstein-Barr virus-positive Hodgkin lymphoma: A Japanese nationwide retrospective survey.

Oncology letters

Yotsumoto M, Ito Y, Hagiwara S, Terui Y, Nagai H, Ota Y, Ajisawa A, Uehira T, Tanuma J, Ohyashiki K, Okada S.
PMID: 30128009
Oncol Lett. 2018 Sep;16(3):3923-3928. doi: 10.3892/ol.2018.9132. Epub 2018 Jul 11.

There has been no comparative clinical study focused on differences in the clinical features of Epstein-Barr virus (EBV)

Cite
Yotsumoto M, Ito Y, Hagiwara S, et al. HIV positivity may not have a negative impact on survival in Epstein-Barr virus-positive Hodgkin lymphoma: A Japanese nationwide retrospective survey. Oncol Lett. 2018;16(3):3923-3928doi: 10.3892/ol.2018.9132.
Yotsumoto, M., Ito, Y., Hagiwara, S., Terui, Y., Nagai, H., Ota, Y., Ajisawa, A., Uehira, T., Tanuma, J., Ohyashiki, K., & Okada, S. (2018). HIV positivity may not have a negative impact on survival in Epstein-Barr virus-positive Hodgkin lymphoma: A Japanese nationwide retrospective survey. Oncology letters, 16(3), 3923-3928. https://doi.org/10.3892/ol.2018.9132
Yotsumoto, Mihoko, et al. "HIV positivity may not have a negative impact on survival in Epstein-Barr virus-positive Hodgkin lymphoma: A Japanese nationwide retrospective survey." Oncology letters vol. 16,3 (2018): 3923-3928. doi: https://doi.org/10.3892/ol.2018.9132
Yotsumoto M, Ito Y, Hagiwara S, Terui Y, Nagai H, Ota Y, Ajisawa A, Uehira T, Tanuma J, Ohyashiki K, Okada S. HIV positivity may not have a negative impact on survival in Epstein-Barr virus-positive Hodgkin lymphoma: A Japanese nationwide retrospective survey. Oncol Lett. 2018 Sep;16(3):3923-3928. doi: 10.3892/ol.2018.9132. Epub 2018 Jul 11. PMID: 30128009; PMCID: PMC6096184.
Copy Download .nbib Format: NLM
Poloxamer 188 enhances apoptosis in a human leukemia cell line.

Molecular medicine reports

Aoki N, Tamura M, Ohyashiki JH, Sugaya M, Hisatomi H.
PMID: 21472296
Mol Med Rep. 2010 Jul-Aug;3(4):669-72. doi: 10.3892/mmr_00000314.

Poloxamer block copolymers have been studied in multiple applications as drug delivery systems (DDS). These A-B-A amphiphilic block copolymers up-regulate the expression of selected genes in cells and alter genetic responses to antineoplastic agents in cancer. One example is...

Cite
Aoki N, Tamura M, Ohyashiki JH, et al. Poloxamer 188 enhances apoptosis in a human leukemia cell line. Mol Med Rep. 2010;3(4):669-72doi: 10.3892/mmr_00000314.
Aoki, N., Tamura, M., Ohyashiki, J. H., Sugaya, M., & Hisatomi, H. (2010). Poloxamer 188 enhances apoptosis in a human leukemia cell line. Molecular medicine reports, 3(4), 669-72. https://doi.org/10.3892/mmr_00000314
Aoki, Nobuo, et al. "Poloxamer 188 enhances apoptosis in a human leukemia cell line." Molecular medicine reports vol. 3,4 (2010): 669-72. doi: https://doi.org/10.3892/mmr_00000314
Aoki N, Tamura M, Ohyashiki JH, Sugaya M, Hisatomi H. Poloxamer 188 enhances apoptosis in a human leukemia cell line. Mol Med Rep. 2010 Jul-Aug;3(4):669-72. doi: 10.3892/mmr_00000314. PMID: 21472296.
Copy Download .nbib Format: NLM
Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders.

Blood cancer journal

Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iida S, Ohyashiki K.
PMID: 22829237
Blood Cancer J. 2012 Jan;2(1):e53. doi: 10.1038/bcj.2011.51. Epub 2012 Jan 20.

Recent studies have demonstrated that one-third of known microRNAs (miRNAs) are stably detectable in plasma. Therefore, we assessed plasma miRNAs to investigate the dynamics of oncomir 17-92a, which is highly expressed in multiple myeloma (MM) patients. The plasma miR-92a...

Cite
Yoshizawa S, Ohyashiki JH, Ohyashiki M, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012;2(1):e53doi: 10.1038/bcj.2011.51.
Yoshizawa, S., Ohyashiki, J. H., Ohyashiki, M., Umezu, T., Suzuki, K., Inagaki, A., Iida, S., & Ohyashiki, K. (2012). Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood cancer journal, 2(1), e53. https://doi.org/10.1038/bcj.2011.51
Yoshizawa, S, et al. "Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders." Blood cancer journal vol. 2,1 (2012): e53. doi: https://doi.org/10.1038/bcj.2011.51
Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iida S, Ohyashiki K. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012 Jan;2(1):e53. doi: 10.1038/bcj.2011.51. Epub 2012 Jan 20. PMID: 22829237; PMCID: PMC3270255.
Copy Download .nbib Format: NLM
Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.

Blood advances

Umezu T, Imanishi S, Azuma K, Kobayashi C, Yoshizawa S, Ohyashiki K, Ohyashiki JH.
PMID: 29296725
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.

The study of bone marrow stromal cells (BMSCs) and the exosomes they secrete is considered promising for cancer therapy. However, little is known about the effect of donor age on BMSCs. In the present study, we investigated the therapeutic...

Cite
Umezu T, Imanishi S, Azuma K, et al. Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis. Blood Adv. 2017;1(13):812-823doi: 10.1182/bloodadvances.2016003251.
Umezu, T., Imanishi, S., Azuma, K., Kobayashi, C., Yoshizawa, S., Ohyashiki, K., & Ohyashiki, J. H. (2017). Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis. Blood advances, 1(13), 812-823. https://doi.org/10.1182/bloodadvances.2016003251
Umezu, Tomohiro, et al. "Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis." Blood advances vol. 1,13 (2017): 812-823. doi: https://doi.org/10.1182/bloodadvances.2016003251
Umezu T, Imanishi S, Azuma K, Kobayashi C, Yoshizawa S, Ohyashiki K, Ohyashiki JH. Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis. Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23. PMID: 29296725; PMCID: PMC5727805.
Copy Download .nbib Format: NLM
SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways.

International journal of oncology

Tauchi T, Ohyashiki K, Yamashita Y, Sugimoto S, Toyama K.
PMID: 21528234
Int J Oncol. 1997 Sep;11(3):471-5. doi: 10.3892/ijo.11.3.471.

The BCR-ABL fusion protein is strongly implicated in the malignant process of Philadelphia (Ph-1)-positive leukemia. The BCR-ABL fusion protein exhibits a deregulated tyrosine kinase activity capable of phosphorylating different cellular substrates in vivo and in vitro. SHP-1 (SHPTP1, PTP1C,...

Cite
Tauchi T, Ohyashiki K, Yamashita Y, et al. SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways. Int J Oncol. 1997;11(3):471-5doi: 10.3892/ijo.11.3.471.
Tauchi, T., Ohyashiki, K., Yamashita, Y., Sugimoto, S., & Toyama, K. (1997). SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways. International journal of oncology, 11(3), 471-5. https://doi.org/10.3892/ijo.11.3.471
Tauchi, T, et al. "SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways." International journal of oncology vol. 11,3 (1997): 471-5. doi: https://doi.org/10.3892/ijo.11.3.471
Tauchi T, Ohyashiki K, Yamashita Y, Sugimoto S, Toyama K. SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways. Int J Oncol. 1997 Sep;11(3):471-5. doi: 10.3892/ijo.11.3.471. PMID: 21528234.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 24 entries